New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
July 13, 2017 – Janssen Biotech announced the FDA approval of Tremfya (guselkumab), for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Download PDF
Return to publications
